دورية أكاديمية
أعرض في EDS

The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.

التفاصيل البيبلوغرافية
العنوان: The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
المؤلفون: Shadick NA; Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA. nshadick@bwh.harvard.edu., Gerlanc NM; Health Analytics, LLC, Columbia, MD, USA., Frits ML; Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA., Stolshek BS; Amgen Inc., Thousand Oaks, CA, USA., Brady BL; Health Analytics, LLC, Columbia, MD, USA., Iannaccone C; Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA., Collier D; Amgen Inc., Thousand Oaks, CA, USA., Cui J; Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA., Mutebi A; Amgen Inc., Thousand Oaks, CA, USA., Weinblatt ME; Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA.
المصدر: Clinical rheumatology [Clin Rheumatol] 2019 Nov; Vol. 38 (11), pp. 3081-3092. Date of Electronic Publication: 2019 Jul 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1434-9949 (Electronic) Linking ISSN: 07703198 NLM ISO Abbreviation: Clin Rheumatol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2008->: Heidelberg : Springer
Original Publication: Brussels : Acta Medica Belgica, [1982-
مواضيع طبية MeSH: Registries*, Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Biological Products/*therapeutic use, Adult ; Aged ; Female ; Humans ; Linear Models ; Male ; Middle Aged ; Severity of Illness Index ; Treatment Outcome
مستخلص: Introduction: Biologics effectively manage symptoms and disease activity in rheumatoid arthritis (RA), but their long-term effects remain unclear.
Method: Longitudinal data were examined from the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry. Linear regression modeled the effect of biologic exposure on changes in disease activity (Disease Activity Score-28 with C-reactive protein [DAS28-CRP]), functional status (modified Health Assessment Questionnaire [mHAQ]), and RA severity (Routine Assessment of Patient Index Data [RAPID3]). Biologic exposure was the ratio of time on a biologic relative to time participating in the BRASS cohort.
Results: The analysis included 1395 RA patients, 82.3% female, with 6783 unique study visits from 2003 to 2015. At the patient's first visit, mean (SD) age was 56.3 (14.2) years and mean (SD) duration of RA was 12.7 (11.9) years. Average follow-up duration was 5.59 years (range, 1-13). Over time, DAS28-CRP, mHAQ, and RAPID3 scores decreased as the biologic exposure ratio increased. In repeated measures regression models, increased biologic exposure was significantly associated with decreased DAS28-CRP score (β = - 0.647; P < 0.001), decreased mHAQ score (β = - 0.096; P < 0.001), and decreased RAPID3 score (β = - 0.724; P < 0.001) during follow-up. Methotrexate use at baseline predicted decreased DAS28-CRP, mHAQ, and RAPID3 scores during follow-up. Biologic use at baseline predicted increased DAS28-CRP or mHAQ during follow-up.
Conclusions: Increased biologic exposure is associated with decreased disease activity, function impairment, and RA severity. Future studies should examine whether earlier initiation of biologics improves patient outcomes in RA.
Trial Registration: ClinicalTrials.gov , NCT01793103 Key Points • Biologics effectively manage symptoms and disease activity in rheumatoid arthritis (RA), but their long-term effects remain unclear. • In this analysis of longitudinal annual population samples of 1395 RA patients in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry, disease activity, function, and severity scores improved as time on biologic therapy increased. • In repeated measures regression models, time on biologic therapy was a significant predictor of improved outcomes for disease activity, function, and RA severity. • Further studies should examine whether earlier initiation of biologics limits the long-term effect of inflammation on RA outcomes.
References: J Rheumatol. 2013 Feb;40(2):127-36. (PMID: 23322461)
Mod Rheumatol. 2018 Mar;28(2):221-226. (PMID: 28701065)
J Rheumatol. 2004 Aug;31(8):1532-7. (PMID: 15290731)
Arthritis Care Res (Hoboken). 2011 Mar;63(3):373-82. (PMID: 20957659)
Arthritis Rheum. 2008 Jun 15;59(6):762-84. (PMID: 18512708)
J Rheumatol. 2012 Aug;39(8):1559-82. (PMID: 21921096)
Arthritis Rheum. 1983 Nov;26(11):1346-53. (PMID: 6639693)
Ann Rheum Dis. 2003 Sep;62(9):835-41. (PMID: 12922955)
Arthritis Rheum. 2006 Jan;54(1):38-46. (PMID: 16385494)
Arthritis Care Res (Hoboken). 2014 Aug;66(8):1142-51. (PMID: 24470077)
Rheumatol Ther. 2017 Dec;4(2):375-389. (PMID: 28840531)
Ann Rheum Dis. 2012 Feb;71(2):213-8. (PMID: 21953343)
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. (PMID: 22473917)
Arthritis Care Res (Hoboken). 2012 Dec;64(12):1794-803. (PMID: 22736476)
J Rheumatol. 2014 Sep;41(9):1761-5. (PMID: 25128506)
EBioMedicine. 2016 Sep;11:302-306. (PMID: 27558858)
Cochrane Database Syst Rev. 2016 May 13;(5):CD012183. (PMID: 27175934)
Rheumatology (Oxford). 2011 Jan;50(1):40-6. (PMID: 20847201)
Rheum Dis Clin North Am. 2009 Nov;35(4):773-8, viii. (PMID: 19962621)
Rheumatology (Oxford). 2015 May;54(5):816-20. (PMID: 25313147)
Arthritis Rheumatol. 2016 Jan;68(1):1-26. (PMID: 26545940)
Ann Rheum Dis. 2011 Aug;70(8):1407-14. (PMID: 21518724)
Rheumatology (Oxford). 2013 Oct;52(10):1809-17. (PMID: 23813577)
Arthritis Rheum. 2009 Jun;60(6):1624-31. (PMID: 19479876)
Arthritis Care Res (Hoboken). 2014 Mar;66(3):464-72. (PMID: 24022870)
Arthritis Rheum. 1998 Oct;41(10):1845-50. (PMID: 9778226)
Nat Genet. 2007 Dec;39(12):1477-82. (PMID: 17982456)
Clin Rheumatol. 2018 Aug;37(8):2275-2280. (PMID: 29869112)
Rheumatology (Oxford). 2012 Feb;51(2):338-46. (PMID: 22096014)
J Rheumatol. 2009 Jul;36(7):1421-8. (PMID: 19487267)
Arthritis Care Res (Hoboken). 2013 Jul;65(7):1183-9. (PMID: 23335345)
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1627-33. (PMID: 24664818)
Arthritis Rheum. 2004 Oct;50(10):3085-92. (PMID: 15476204)
Clin Rheumatol. 2017 Jun;36(6):1215-1220. (PMID: 28251392)
Arthritis Rheum. 2005 Nov;52(11):3381-90. (PMID: 16258899)
Arthritis Rheum. 1995 Jan;38(1):44-8. (PMID: 7818570)
Medicine (Baltimore). 2018 Mar;97(13):e9930. (PMID: 29595700)
Arthritis Rheum. 2005 Jan;52(1):27-35. (PMID: 15641102)
Ann Rheum Dis. 2014 Mar;73(3):492-509. (PMID: 24161836)
Ann Rheum Dis. 2012 May;71(5):681-6. (PMID: 21994234)
Arch Intern Med. 2006 Dec 11-25;166(22):2490-4. (PMID: 17159015)
معلومات مُعتمدة: NA Amgen (US)
فهرسة مساهمة: Keywords: Biologics; Disease activity; Exposure; Function; Rheumatoid arthritis; Severity
سلسلة جزيئية: ClinicalTrials.gov NCT01793103
المشرفين على المادة: 0 (Antirheumatic Agents)
0 (Biological Products)
تواريخ الأحداث: Date Created: 20190730 Date Completed: 20200330 Latest Revision: 20200330
رمز التحديث: 20231215
DOI: 10.1007/s10067-019-04649-4
PMID: 31353421
قاعدة البيانات: MEDLINE
الوصف
تدمد:1434-9949
DOI:10.1007/s10067-019-04649-4